We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Pfizer Settles Lipitor Battles With Ranbaxy

Law360 (June 18, 2008, 12:00 AM EDT) -- Pfizer Inc. has reached an agreement with generics maker Ranbaxy Laboratories Ltd. to settle most of the worldwide patent litigation between the two companies over the blockbuster cholesterol-reducing treatment Lipitor.

Under the settlement, Ranbaxy will be able to sell generic versions of Lipitor and Caduet starting Nov. 20, 2011. Caduet is a combination of Lipitor and a high blood pressure medication called Norvasc, another Pfizer product.

Lipitor is the world's most prescribed drug, with worldwide sales in 2007 of $12.7 billion. The largest market for Lipitor...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.